Categories Earnings, Health Care

Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot

— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.

— Product revenues grew by 30% to $39.3 million versus $38.97 million expected. The top line was driven by an increase in the US net product revenue.

Earnings Update by AlphaStreet

— The supply of free drugs distributed to eligible patients in the U.S. through the Rubraca patient assistance program for Q4 2019 was 18% of the overall US commercial supply, compared to 26% reported in Q4 2018.

— Research and development expenses increased by 2% year-over-year due primarily to higher research and development costs for rucaparib clinical trials.

— The company believes it has sufficient cash, cash equivalents, and available-for-sale securities to fund its operating plan into the second half of 2021. This is based on anticipated revenue, spending, available financing sources, and existing cash.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Also Read:  Tyson Foods Q4 earnings, revenue beat estimates

Most Popular

Nutanix reports narrower loss than expected in Q1

Nutanix (NASDAQ: NTNX) reported first-quarter 2021 financial results after the regular trading hours on Monday. The software firm reported Q1 revenue of $312.8 million, down 0.6% year-over-year, but higher than

Urban Outfitters (URBN) Q3 Earnings: Key financials and quarterly highlights

Urban Outfitters, Inc. (NASDAQ: URBN) reported third quarter 2021 earnings results today. Net sales decreased 1.8% year-over-year to $970 million. Net income was $77 million, or $0.78 per share, compared to

Earnings reports to watch for the week of Nov. 23

After starting the week on a positive note, major stock indexes witnessed volatility and slipped mid-week. Meanwhile, the S&P 500 index regained a part of the lost momentum and closed

Top